Pre- and Postlicensure Animal Efficacy Studies Comparing Anthrax Antitoxins

Area of Science:

• Biodefense and biosecurity
• Infectious disease research
• Pharmacology and toxicology

Background:

• Bacillus anthracis spores pose a significant bioweapons threat.
• Post-exposure prophylaxis with antimicrobials is the primary defense against anthrax.
• Antitoxins targeting protective antigen are crucial for treating systemic anthrax infections.

Purpose of the Study:

• To compare the efficacy of three US government-developed antitoxins against Bacillus anthracis.
• To evaluate the therapeutic benefit of anthrax immunoglobulin intravenous (AIGIV), raxibacumab, and obiltoxaximab.
• To provide data for prioritizing antitoxin deployment in biodefense.

Main Methods:

• Utilized a New Zealand White rabbit model of inhalation anthrax.
• Administered intravenous antitoxin treatments post-onset of antigenemia.
• Assessed survival rates following a lethal aerosolized dose of B. anthracis spores.

Main Results:

• All three antitoxins (AIGIV, raxibacumab, obiltoxaximab) demonstrated superiority over placebo.
• In postlicensure studies, raxibacumab and obiltoxaximab showed greater efficacy than AIGIV.
• No significant difference in efficacy was found between raxibacumab and obiltoxaximab.

Conclusions:

• The study highlights the relative therapeutic benefits of the three antitoxins.
• Data supports a rationale for prioritizing the deployment of raxibacumab and obiltoxaximab over AIGIV.
• These findings contribute to optimizing biodefense strategies against anthrax.